2019 International Congress Archives - Page 26 of 217

1:45pm-3:15pm: Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration

J. Cedarbaum, K. Taylor, D. Hill, R. Alexander, Y. Luo, R. Rubens, N. Zach, J. Cosman, A. Dowling, K. Fisher, L. Oliva, J. Hitchcock, M. Lawton, D. Conrado, K. Romero, M. Minchik, D. Meulien, B. Yang, M. Forman, L. Bataille, D. Dexter, J. Gallagher, M. Braxenthaler, M. Lindemann, B. Boroojerdi, G. Stebbins, B. Bloem, M. Hu, E. Dorsey, D. Stephenson (Cambridge, MA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Encephalomyelopathy Due to Cerebrotendinous Xanthomatosis

ACO. Oliveira, LFV. Vasconcellos, BXC. Cordeiro, LLN. Najar (Rio de Janeiro, Brazil)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3

1:45pm-3:15pm: Entity of excessive daytime sleepiness in Parkinson’s disease

O. Iakovleva, O. Levin, M. Poluektov (Moscow, Russian Federation)

Restless Leg Syndrome, RBD and Other Sleep Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Epidemiological study of multiple system atrophy: data from HoRC-MSA Project 2014-2019

M. Matsushima, I. Yabe, K. Sakushima, I. Iwata, Y. Kanatani, N. Nishimoto, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, A. Tamakoshi, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Evaluating IL6 and mitochondrial DNA levels as a potential biomarker in carriers of Parkin and PINK1 mutations

M. Borsche, I. König, S. Delcambre, S. Petrucci, A. Balck, T. Gasser, N. Brüggemann, S. Pereira, K. Badanjak, K. Brockmann, E M. Valente, R. Youle, A. Grünewald, C. Klein (Lübeck, Germany)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Evaluating Implementation of an Evidence-based Physical and Occupational Therapy (LSVT BIG®) for Parkinson’s Disease: Germany, France and Japan

C. Fox, L. Guse, L. Ramig (Tucson, AZ, USA)

Physical and Occupational Therapy · Les Muses Terrace, Level 3

1:45pm-3:15pm: Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases

A. Shim, V. Abler, N. Rashid (San Diego, CA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study

R. Pahwa, R. Dorsey, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, N. Gupta, I. Pan, Y. Bao, D. Heldman (Kansas City, KS, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Evaluation and Intervention of Aquatic Physiotherapy in People with Parkinson’s Disease: Repercussions on Balance

V. Israel, D. Iucksch, J. Siega, A. Silva, B. Yamaguchi, M. Ferreira (Curitiba, Brazil)

Physical and Occupational Therapy · Les Muses Terrace, Level 3